Pfizer NDA submissions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer is planning to submit an NDA for pregabalin in 2002 for add-on epilepsy, neuropathic pain and generalized anxiety disorder, the company says in a Dec. 18 analysts meeting. The firm had previously said it would file for epilepsy and pain in third quarter 2001. Other Pfizer filings expected in the next five years include: CP-526,555 for smoking cessation, pagoclone for anxiety, CP-122-721 for depression, darifenacin for overactive bladder, capravirine for AIDS and UK-338,003 for benign prostatic hyperplasia and erectile dysfunction